EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma
This study has rationalized the next development of a combination therapy with AZD5582 and nanosomal TRAIL for cancer treatment.
Source: Journal of Molecular Medicine - Category: Molecular Biology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Molecular Biology | Nanotechnology | Study